Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Menhycia
- Development stage
- Unknown
- Lead developer
- CanSino Biologics
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Menhycia is a quadrivalent meningococcal conjugate vaccine developed by CanSino Biologics for the prevention of epidemic cerebrospinal meningitis and meningoencephalitis caused by *Neisseria meningitidis* serogroups A, C, Y, and W135. The vaccine consists of purified capsular polysaccharides from these four serogroups, each covalently conjugated to the CRM197 carrier protein, a non-toxic mutant of diphtheria toxin. This conjugation enhances the immune response by converting polysaccharide antigens into T-cell dependent antigens, which is particularly effective in infants and young children. Menhycia is approved in China for use in children from 3 months to 6 years of age.
- Brand names
- Menhycia
- Other names
- Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197)ACYW135 Meningococcal Conjugate VaccineACYW-135 Meningococcal Conjugate VaccineACYW 135 Meningococcal Conjugate VaccineMCV4-CRM197MCV-4-CRM197MCV 4-CRM197
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)
Beyond the preview
Go deeper on Menhycia.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Menhycia.